Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort

Background: Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality in critically ill patients are poorly understood. Methods: Following the critical de...

Full description

Bibliographic Details
Main Authors: Pedro David Wendel Garcia, Thierry Fumeaux, Philippe Guerci, Dorothea Monika Heuberger, Jonathan Montomoli, Ferran Roche-Campo, Reto Andreas Schuepbach, Matthias Peter Hilty
Format: Article
Language:English
Published: Elsevier 2020-08-01
Series:EClinicalMedicine
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589537020301930
id doaj-6341df6e7acc4a90aff6899001633c5c
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Pedro David Wendel Garcia
Thierry Fumeaux
Philippe Guerci
Dorothea Monika Heuberger
Jonathan Montomoli
Ferran Roche-Campo
Reto Andreas Schuepbach
Matthias Peter Hilty
spellingShingle Pedro David Wendel Garcia
Thierry Fumeaux
Philippe Guerci
Dorothea Monika Heuberger
Jonathan Montomoli
Ferran Roche-Campo
Reto Andreas Schuepbach
Matthias Peter Hilty
Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
EClinicalMedicine
COVID-19
Coronavirus
Pandemic
Public health
Acute respiratory distress syndrome
author_facet Pedro David Wendel Garcia
Thierry Fumeaux
Philippe Guerci
Dorothea Monika Heuberger
Jonathan Montomoli
Ferran Roche-Campo
Reto Andreas Schuepbach
Matthias Peter Hilty
author_sort Pedro David Wendel Garcia
title Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
title_short Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
title_full Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
title_fullStr Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
title_full_unstemmed Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohort
title_sort prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with covid-19 in europe: initial report of the international risc-19-icu prospective observational cohort
publisher Elsevier
series EClinicalMedicine
issn 2589-5370
publishDate 2020-08-01
description Background: Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality in critically ill patients are poorly understood. Methods: Following the critical developments in ICUs in regions experiencing early inception of the pandemic, the European-based, international RIsk Stratification in COVID-19 patients in the Intensive Care Unit (RISC-19-ICU) registry was created to provide near real-time assessment of patients developing critical illness due to COVID-19. Findings: As of April 22, 2020, 639 critically ill patients with confirmed SARS-CoV-2 infection were included in the RISC-19-ICU registry. Of these, 398 had deceased or been discharged from the ICU. ICU-mortality was 24%, median length of stay 12 (IQR, 5–21) days. ARDS was diagnosed in 74%, with a minimum P/F-ratio of 110 (IQR, 80–148). Prone positioning, ECCO2R, or ECMO were applied in 57%. Off-label therapies were prescribed in 265 (67%) patients, and 89% of all bloodstream infections were observed in this subgroup (n = 66; RR=3·2, 95% CI [1·7–6·0]). While PCT and IL-6 levels remained similar in ICU survivors and non-survivors throughout the ICU stay (p = 0·35, 0·34), CRP, creatinine, troponin, d-dimer, lactate, neutrophil count, P/F-ratio diverged within the first seven days (p<0·01). On a multivariable Cox proportional-hazard regression model at admission, creatinine, d-dimer, lactate, potassium, P/F-ratio, alveolar-arterial gradient, and ischemic heart disease were independently associated with ICU-mortality. Interpretation: The European RISC-19-ICU cohort demonstrates a moderate mortality of 24% in critically ill patients with COVID-19. Despite high ARDS severity, mechanical ventilation incidence was low and associated with more rescue therapies. In contrast to risk factors in hospitalized patients reported in other studies, the main mortality predictors in these critically ill patients were markers of oxygenation deficit, renal and microvascular dysfunction, and coagulatory activation. Elevated risk of bloodstream infections underscores the need to exercise caution with off-label therapies.
topic COVID-19
Coronavirus
Pandemic
Public health
Acute respiratory distress syndrome
url http://www.sciencedirect.com/science/article/pii/S2589537020301930
work_keys_str_mv AT pedrodavidwendelgarcia prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT thierryfumeaux prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT philippeguerci prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT dorotheamonikaheuberger prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT jonathanmontomoli prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT ferranrochecampo prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT retoandreasschuepbach prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
AT matthiaspeterhilty prognosticfactorsassociatedwithmortalityriskanddiseaseprogressionin639criticallyillpatientswithcovid19ineuropeinitialreportoftheinternationalrisc19icuprospectiveobservationalcohort
_version_ 1724961048689115136
spelling doaj-6341df6e7acc4a90aff6899001633c5c2020-11-25T02:00:22ZengElsevierEClinicalMedicine2589-53702020-08-0125100449Prognostic factors associated with mortality risk and disease progression in 639 critically ill patients with COVID-19 in Europe: Initial report of the international RISC-19-ICU prospective observational cohortPedro David Wendel Garcia0Thierry Fumeaux1Philippe Guerci2Dorothea Monika Heuberger3Jonathan Montomoli4Ferran Roche-Campo5Reto Andreas Schuepbach6Matthias Peter Hilty7The RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland; Institute of Intensive Care Medicine, University Hospital of Zurich, Rämistrasse 100, Zurich 8091, Switzerland; Corresponding author.The RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland; Soins intensifs, Groupement Hospitalier de l'Ouest Lémanique - Hopital de Nyon, Nyon, SwitzerlandThe RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland; Department of Anesthesiology and Critical care Medicine, University Hospital of Nancy, FranceInstitute of Intensive Care Medicine, University Hospital of Zurich, Rämistrasse 100, Zurich 8091, SwitzerlandThe RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland; Department of Intensive Care Medicine, Erasmus medical Center, Rotterdam, NetherlandsServei de Medicina intensiva, Hospital Verge de la Cinta, Tortosa, Tarragona, SpainThe RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland; Institute of Intensive Care Medicine, University Hospital of Zurich, Rämistrasse 100, Zurich 8091, SwitzerlandThe RISC-19-ICU registry board, University of Zurich, Zurich, Switzerland; Institute of Intensive Care Medicine, University Hospital of Zurich, Rämistrasse 100, Zurich 8091, SwitzerlandBackground: Coronavirus disease 2019 (COVID-19) is associated with a high disease burden with 10% of confirmed cases progressing towards critical illness. Nevertheless, the disease course and predictors of mortality in critically ill patients are poorly understood. Methods: Following the critical developments in ICUs in regions experiencing early inception of the pandemic, the European-based, international RIsk Stratification in COVID-19 patients in the Intensive Care Unit (RISC-19-ICU) registry was created to provide near real-time assessment of patients developing critical illness due to COVID-19. Findings: As of April 22, 2020, 639 critically ill patients with confirmed SARS-CoV-2 infection were included in the RISC-19-ICU registry. Of these, 398 had deceased or been discharged from the ICU. ICU-mortality was 24%, median length of stay 12 (IQR, 5–21) days. ARDS was diagnosed in 74%, with a minimum P/F-ratio of 110 (IQR, 80–148). Prone positioning, ECCO2R, or ECMO were applied in 57%. Off-label therapies were prescribed in 265 (67%) patients, and 89% of all bloodstream infections were observed in this subgroup (n = 66; RR=3·2, 95% CI [1·7–6·0]). While PCT and IL-6 levels remained similar in ICU survivors and non-survivors throughout the ICU stay (p = 0·35, 0·34), CRP, creatinine, troponin, d-dimer, lactate, neutrophil count, P/F-ratio diverged within the first seven days (p<0·01). On a multivariable Cox proportional-hazard regression model at admission, creatinine, d-dimer, lactate, potassium, P/F-ratio, alveolar-arterial gradient, and ischemic heart disease were independently associated with ICU-mortality. Interpretation: The European RISC-19-ICU cohort demonstrates a moderate mortality of 24% in critically ill patients with COVID-19. Despite high ARDS severity, mechanical ventilation incidence was low and associated with more rescue therapies. In contrast to risk factors in hospitalized patients reported in other studies, the main mortality predictors in these critically ill patients were markers of oxygenation deficit, renal and microvascular dysfunction, and coagulatory activation. Elevated risk of bloodstream infections underscores the need to exercise caution with off-label therapies.http://www.sciencedirect.com/science/article/pii/S2589537020301930COVID-19CoronavirusPandemicPublic healthAcute respiratory distress syndrome